Details for New Drug Application (NDA): 205343
✉ Email this page to a colleague
NDA 205343 describes FLURANDRENOLIDE, which is a drug marketed by Chartwell Rx, Alpharma Us Pharms, Padagis Israel, and Teligent, and is included in five NDAs. It is available from two suppliers. Additional details are available on the FLURANDRENOLIDE profile page.
The generic ingredient in FLURANDRENOLIDE is flurandrenolide. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the flurandrenolide profile page.
The generic ingredient in FLURANDRENOLIDE is flurandrenolide. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the flurandrenolide profile page.
Summary for 205343
| Tradename: | FLURANDRENOLIDE |
| Applicant: | Chartwell Rx |
| Ingredient: | flurandrenolide |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | LOTION;TOPICAL | Strength | 0.05% | ||||
| Approval Date: | Dec 22, 2016 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
